OT03 | BGB‐11417‐302, A PHASE 3, RANDOMIZED, DOUBLE‐BLIND STUDY OF SONROTOCLAX (BGB‐11417) + ZANUBRUTINIB VERSUS PLACEBO + ZANUBRUTINIB IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available
10.1002/hon.70093_ot03